Alendronate slows down aortic stenosis progression in osteoporotic patients: An observational prospective study

BACKGROUND: Aortic stenosis (AS) is the most common primary valvular disease. Currently, there is no pharmacological approach for the medical management of AS. We investigated the effect of osteoporosis therapy with alendronate on hemodynamic progression in patients concurrently affected by AS and o...

Descripción completa

Detalles Bibliográficos
Autores principales: Alishiri, Gholamhossein, Heshmat-Ghahdarijani, Kiyan, Hashemi, Mohammad, Zavar, Reihaneh, Farahani, Maryam Moshkani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554420/
https://www.ncbi.nlm.nih.gov/pubmed/33088302
http://dx.doi.org/10.4103/jrms.JRMS_408_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554420/
https://www.ncbi.nlm.nih.gov/pubmed/33088302
http://dx.doi.org/10.4103/jrms.JRMS_408_20

Ejemplares similares